Business Wire

Dyne Therapeutics Demonstrates FORCE™ Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy

WALTHAM, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced data demonstrating enhanced ...
Seeking Alpha

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease - “The full breadth and versatility of our FORCE platform is on ...
Medical Xpress

News on muscle force

The ability of skeletal muscle to produce force (contractile function) and contraction-stimulated glucose uptake (increase in clearing sugar from bloodstream) do not differ by time of day, regardless ...